Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 20/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29339903 | 0.95 | RET (0.57) | RET | |
| SCHEMBL31010008 | 0.95 | RET (0.57) | RET | |
| SCHEMBL22118655 | 0.94 | RET (0.54) | RET | |
| SCHEMBL29341043 | 0.90 | RET (0.60) | RET | |
| SCHEMBL31009800 | 0.90 | RET (0.54) | RET | |
| SCHEMBL29339828 | 0.90 | RET (0.54) | RET | |
| SCHEMBL22118605 | 0.90 | RET (0.62) | RET | |
| SCHEMBL29341045 | 0.89 | RET (0.58) | RET | |
| SCHEMBL25222765 | 0.88 | RET (0.58) | RET | |
| SCHEMBL25687744 | 0.88 | RET (0.76) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270211-A1 | COMPOUNDS FOR FGFR INHIBITION | COGENT BIOSCIENCES, INC. | 2025-08-28 | — | — | US | disclosed |
| WO-2025034912-A9 | COMPOUNDS FOR FGFR INHIBITION | COGENT BIOSCIENCES, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025034912-A2 | COMPOUNDS FOR FGFR INHIBITION | COGENT BIOSCIENCES, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| EP-4192458-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC. | 2022-03-17 | — | — | US | disclosed |
| WO-2022032026-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| EP-3898626-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | Array Biopharma, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-113490666-A | Substituted pyrazolo [1,5-A ] pyridine compounds as inhibitors of FGFR tyrosine kinases | 奥瑞生物药品公司 | 2021-10-08 | — | — | CN | disclosed |
| WO-2020131627-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC. (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270211-A1 | COMPOUNDS FOR FGFR INHIBITION | FGFR1, FGFR4, FGFR3 | RET 12/4885 |
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | FGFR1, FGFR4, FGFR3 | RET 11/4885 |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | RET, HRAS, RBX1 | RET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.